David Lye

Specialty: Infectious Disease

Location: Unknown, Unknown, Global

Tier: ELITE

H-Index: 96

Years Active: 0

Hospital Affiliations

• National Centre for Infectious Diseases - Member

Key Publications

1. "Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance: A Randomized Clinical Trial." - JAMA (2018)
2. "Remdesivir for the Treatment of Covid-19 - Final Report." - N Engl J Med (2020)
3. "Monkeypox: disease epidemiology, host immunity and clinical interventions." - Nat Rev Immunol (2022)
4. "Early Oral Antibiotic Switch in Staphylococcus aureus Bacteraemia: The Staphylococcus aureus Network Adaptive Platform (SNAP) Trial Early Oral Switch Protocol." - Clin Infect Dis (2024)
5. "Meropenem Versus Piperacillin-Tazobactam for Definitive Treatment of Bloodstream Infections Caused by AmpC β-Lactamase-Producing Enterobacter spp, Citrobacter freundii, Morganella morganii, Providencia spp, or Serratia marcescens: A Pilot Multicenter Randomized Controlled Trial (MERINO-2)." - Open Forum Infect Dis (2021)

Knowledge Graph Relationships

David Lye is a Infectious Disease specialist affiliated with National Centre for Infectious Diseases. Authored 5 scholarly articles.